ATKR vs HUBG

The Advanced Deterministic Scorecard reveals a weak financial health profile with a Piotroski F-Score of just 2/9, indicating significant deterioration in fundamental performance. Despite a strong Current Ratio and manageable Debt/Equity, the company is unprofitable on a net basis (Profit Margin: -0.53%, ROE: -1.03%) and facing sharp earnings contraction (YoY EPS Growth: -71.6%). Valuation appears stretched relative to peers with a Forward P/E of 12.23 while operating in a declining revenue environment (Revenue Growth YoY: -4.60%), and the lack of a Graham Number or Altman Z-Score limits confidence in intrinsic value and solvency safety. Although the dividend yield is modestly attractive at 1.80% with a sustainable payout ratio, weak earnings momentum, deteriorating profitability, and neutral insider activity suggest substantial downside risks.

HUBG exhibits strong fundamental health with a Piotroski F-Score of 7/9 and a very conservative debt-to-equity ratio of 0.28. While the current price of $38.97 sits above the defensive Graham Number ($33.01), it remains well below the growth-based intrinsic value of $51.33. The company is successfully expanding margins, as evidenced by 20.5% earnings growth despite a 5.3% decline in revenue. Despite bearish technicals and recent insider selling, the long-term earnings track record and valuation metrics suggest significant upside.